X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Divis Laboratories with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs TEVA PHARMA (Israel) - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   TEVA PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
TEVA PHARMA
Dec-13
DIVIS LABORATORIES/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1423,029-   
Low Rs5332,631-   
Sales per share (Unadj.) Rs146.61,738.2-  
Earnings per share (Unadj.) Rs33.0108.6-  
Cash flow per share (Unadj.) Rs38.4249.1-  
Dividends per share (Unadj.) Rs10.0095.05-  
Dividend yield (eoy) %1.23.4 35.5%  
Book value per share (Unadj.) Rs222.81,930.8-  
Shares outstanding (eoy) m265.47848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.71.6 350.9%   
Avg P/E ratio x25.326.1 97.3%  
P/CF ratio (eoy) x21.811.4 191.9%  
Price / Book Value ratio x3.81.5 256.4%  
Dividend payout %30.387.5 34.6%   
Avg Mkt Cap Rs m222,3182,399,704 9.3%   
No. of employees `00010.844.9 23.9%   
Total wages/salary Rs m4,5610-   
Avg. sales/employee Rs Th3,616.032,795.3 11.0%   
Avg. wages/employee Rs Th423.80-   
Avg. net profit/employee Rs Th814.92,048.7 39.8%   
INCOME DATA
Net Sales Rs m38,9151,473,984 2.6%  
Other income Rs m1,1340-   
Total revenues Rs m40,0491,473,984 2.7%   
Gross profit Rs m12,617403,651 3.1%  
Depreciation Rs m1,425119,144 1.2%   
Interest Rs m1328,951 0.0%   
Profit before tax Rs m12,313255,556 4.8%   
Minority Interest Rs m01,161 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-167,759 0.0%   
Tax Rs m3,543-3,120 -113.6%   
Profit after tax Rs m8,77092,079 9.5%  
Gross profit margin %32.427.4 118.4%  
Effective tax rate %28.8-1.2 -2,356.9%   
Net profit margin %22.56.2 360.8%  
BALANCE SHEET DATA
Current assets Rs m45,351995,523 4.6%   
Current liabilities Rs m6,507868,180 0.7%   
Net working cap to sales %99.88.6 1,155.4%  
Current ratio x7.01.1 607.8%  
Inventory Days Days12791 139.5%  
Debtors Days Days9596 99.2%  
Net fixed assets Rs m21,160481,436 4.4%   
Share capital Rs m5313,628 14.6%   
"Free" reserves Rs m58,6250-   
Net worth Rs m59,1561,637,316 3.6%   
Long term debt Rs m0753,681 0.0%   
Total assets Rs m67,8323,368,525 2.0%  
Interest coverage x926.89.8 9,431.2%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.60.4 131.1%   
Return on assets %12.93.6 360.4%  
Return on equity %14.85.6 263.6%  
Return on capital %20.84.9 422.5%  
Exports to sales %00-   
Imports to sales %21.80-   
Net fx Rs m23,3170-   
CASH FLOW
From Operations Rs m7,759234,877 3.3%  
From Investments Rs m-4,783-83,226 5.7%  
From Financial Activity Rs m-3,142-281,750 1.1%  
Net Cashflow Rs m-166-130,100 0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.56 Rs / USD

Compare DIVIS LABORATORIES With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare DIVIS LABORATORIES With: FDC LTD.  AUROBINDO PHARMA  WOCKHARDT LTD.  FRESENIUS KABI ONCO.  J.B.CHEMICALS  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views On News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Nov 13, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS